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1. INTRODUCTION {#ejh13478-sec-0001}
===============

Following the emergence of Coronavirus Disease 2019 (COVID‐19) in Wuhan (China) around December 2019,[^1^](#ejh13478-bib-0001){ref-type="ref"} the infection has become a pandemic, decimating over three hundred thousand globally.[^2^](#ejh13478-bib-0002){ref-type="ref"} The severity of COVID‐19 cases reported hitherto has varied greatly from asymptomatic to severe pneumonia and thromboembolism, accompanied by overt respiratory failure with subsequent mortality.[^3^](#ejh13478-bib-0003){ref-type="ref"}, [^4^](#ejh13478-bib-0004){ref-type="ref"}, [^5^](#ejh13478-bib-0005){ref-type="ref"} As the COVID‐19 pandemic continues to evolve, potential risk factors that may predispose individuals to fatal outcomes are increasingly becoming topical. There are ongoing epidemiological investigations and discussions of potentially at‐risk populations and ethnicities.[^6^](#ejh13478-bib-0006){ref-type="ref"}, [^7^](#ejh13478-bib-0007){ref-type="ref"} An improved understanding of the risk factors as well as clinical course for severe COVID‐19 may shed some light on novel personalized approaches to optimize clinical care and outcomes.

Emerging trends in the United States suggest possibly higher mortality rates of COVID‐19 among African Americans,[^8^](#ejh13478-bib-0008){ref-type="ref"}, [^9^](#ejh13478-bib-0009){ref-type="ref"} although epidemiological study data with adequate denominator[^10^](#ejh13478-bib-0010){ref-type="ref"} across board is pending. There is no doubt that socio‐economic determinants of health play crucial roles in health inequities and disease trajectory.[^11^](#ejh13478-bib-0011){ref-type="ref"} Nevertheless, interplay of genetic and environmental factors contributes to overall clinical outcomes in a substantial burden of human diseases.[^12^](#ejh13478-bib-0012){ref-type="ref"}, [^13^](#ejh13478-bib-0013){ref-type="ref"}, [^14^](#ejh13478-bib-0014){ref-type="ref"}, [^15^](#ejh13478-bib-0015){ref-type="ref"}, [^16^](#ejh13478-bib-0016){ref-type="ref"}, [^17^](#ejh13478-bib-0017){ref-type="ref"} Sickle cell disease (SCD) disproportionately affects Black/African Americans in the United States as well as forebearers from sub‐Saharan Africa, the Western Hemisphere (South America, the Caribbean, and Central America), and some Mediterranean countries.[^18^](#ejh13478-bib-0018){ref-type="ref"}, [^19^](#ejh13478-bib-0019){ref-type="ref"}, [^20^](#ejh13478-bib-0020){ref-type="ref"} Increasing evidence suggests that COVID‐19 pneumonia can cause acute chest syndrome (ACS), a potentially life‐threatening complication in SCD.[^21^](#ejh13478-bib-0021){ref-type="ref"}, [^22^](#ejh13478-bib-0022){ref-type="ref"}, [^23^](#ejh13478-bib-0023){ref-type="ref"} These observations raise questions on the potential contributions of SCD‐related complications, for instance thromboembolism to the severity of COVID‐19. Increasing evidence suggests a higher risk of venous thromboembolism in COVID‐19,[^3^](#ejh13478-bib-0003){ref-type="ref"}, [^4^](#ejh13478-bib-0004){ref-type="ref"}, [^5^](#ejh13478-bib-0005){ref-type="ref"} prompting ongoing considerations and potential applications of prophylactic anticoagulation[^24^](#ejh13478-bib-0024){ref-type="ref"} and therapeutic thrombolysis.[^25^](#ejh13478-bib-0025){ref-type="ref"}

Being the carrier state for an autosomal recessive genetic disorder, sickle cell trait is frequently perceived to be a relatively benign condition; however, this remains controversial.[^26^](#ejh13478-bib-0026){ref-type="ref"}, [^27^](#ejh13478-bib-0027){ref-type="ref"}, [^28^](#ejh13478-bib-0028){ref-type="ref"}, [^29^](#ejh13478-bib-0029){ref-type="ref"}, [^30^](#ejh13478-bib-0030){ref-type="ref"} Conditions of increased oxygen demands may trigger sickle‐related complications in heterozygotes.[^31^](#ejh13478-bib-0031){ref-type="ref"}, [^32^](#ejh13478-bib-0032){ref-type="ref"}, [^33^](#ejh13478-bib-0033){ref-type="ref"}, [^34^](#ejh13478-bib-0034){ref-type="ref"}, [^35^](#ejh13478-bib-0035){ref-type="ref"}, [^36^](#ejh13478-bib-0036){ref-type="ref"}, [^37^](#ejh13478-bib-0037){ref-type="ref"}, [^38^](#ejh13478-bib-0038){ref-type="ref"}, [^39^](#ejh13478-bib-0039){ref-type="ref"}, [^40^](#ejh13478-bib-0040){ref-type="ref"}, [^41^](#ejh13478-bib-0041){ref-type="ref"}, [^42^](#ejh13478-bib-0042){ref-type="ref"}, [^43^](#ejh13478-bib-0043){ref-type="ref"}, [^44^](#ejh13478-bib-0044){ref-type="ref"} COVID‐19 causes severe pneumonia in at‐risk individuals resulting in an increased oxygen demand. Yet, the notion that COVID‐19 associated pneumonia may result in poor clinical outcomes in sickle cell trait if unrecognized is less discussed. This mini‐review highlights the putative risks of severe COVID‐19 in SCD and sickle cell trait, with a focus on the risks associated with the heterozygous state.

2. EPIDEMIOLOGY AND MOLECULAR PATHOGENESIS OF SICKLE CELL TRAIT {#ejh13478-sec-0002}
===============================================================

Sickle cell trait affects approximately 300 million people globally.[^45^](#ejh13478-bib-0045){ref-type="ref"} Owing to its protective effects against severe malaria, sickle cell trait confers an evolutionary survival advantage.[^46^](#ejh13478-bib-0046){ref-type="ref"} The highest prevalence of sickle cell trait is in Africa and among people of African descent across the world.[^18^](#ejh13478-bib-0018){ref-type="ref"}, [^47^](#ejh13478-bib-0047){ref-type="ref"} In the United States, national estimates of the sickle cell trait prevalence from Newborn Screening data suggest about 1.5% with about 8% prevalence among African Americans, almost 3 million individuals.[^48^](#ejh13478-bib-0048){ref-type="ref"} About 1%‐3% of the European population carries a gene mutation for hemoglobinopathy, particularly sickle cell trait.[^49^](#ejh13478-bib-0049){ref-type="ref"}, [^50^](#ejh13478-bib-0050){ref-type="ref"}, [^51^](#ejh13478-bib-0051){ref-type="ref"}, [^52^](#ejh13478-bib-0052){ref-type="ref"} Approximately 5% of the world carry a significant hemoglobin gene variant.[^52^](#ejh13478-bib-0052){ref-type="ref"} A recent global meta‐estimate of birth prevalence of SCD was approximately 112 per 100 000 live births with about 10 folds higher birth prevalence in Africa, 1125 per 100 000.[^18^](#ejh13478-bib-0018){ref-type="ref"}, [^47^](#ejh13478-bib-0047){ref-type="ref"}

Being the heterozygous state, red blood cells in sickle cell trait have one copy of normal adult hemoglobin (Hb) denoted as HbA and one copy of mutant Hb (HbS) resulting in Hb genotype of HbAS.[^53^](#ejh13478-bib-0053){ref-type="ref"} HbS results from a missense mutation causing amino acid substitution whereby valine replaces glutamic acid in the 6th codon of the β chain.[^54^](#ejh13478-bib-0054){ref-type="ref"}, [^55^](#ejh13478-bib-0055){ref-type="ref"} The presence of HbA attenuates HbS phenotype, reducing the probability of polymer formation; hence, normal hematological parameters are observed in the majority of individuals with sickle cell trait.[^54^](#ejh13478-bib-0054){ref-type="ref"} Nevertheless, cumulative evidence suggests that hypoxia may trigger sickle‐related complications such as splenic infarction, thromboembolism, papillary necrosis, exertional rhabdomyolysis, and death in sickle cell trait.[^26^](#ejh13478-bib-0026){ref-type="ref"}, [^31^](#ejh13478-bib-0031){ref-type="ref"}, [^32^](#ejh13478-bib-0032){ref-type="ref"}, [^33^](#ejh13478-bib-0033){ref-type="ref"}, [^34^](#ejh13478-bib-0034){ref-type="ref"}, [^35^](#ejh13478-bib-0035){ref-type="ref"}, [^36^](#ejh13478-bib-0036){ref-type="ref"}, [^37^](#ejh13478-bib-0037){ref-type="ref"}, [^38^](#ejh13478-bib-0038){ref-type="ref"}, [^39^](#ejh13478-bib-0039){ref-type="ref"}, [^40^](#ejh13478-bib-0040){ref-type="ref"}, [^43^](#ejh13478-bib-0043){ref-type="ref"}, [^44^](#ejh13478-bib-0044){ref-type="ref"}

3. COVID‐19 PNEUMONIA IN SCD: POTENTIAL RELEVANCE TO SICKLE CELL TRAIT {#ejh13478-sec-0003}
======================================================================

As of May 16, 2020, 15 SCD patients with COVID‐19 have been reported in the clinical scientific literature indexed in PubMed.[^56^](#ejh13478-bib-0056){ref-type="ref"} These studies are summarized in Table [1](#ejh13478-tbl-0001){ref-type="table"}. Beerkens et al[^57^](#ejh13478-bib-0057){ref-type="ref"} described the first documented case of SCD patient who developed ACS in the setting of COVID‐19. The index case was on maintenance hydroxyurea therapy for SCD. He was initially started on hydroxychloroquine for severe COVID‐19 pneumonia. He later developed ACS, requiring urgent exchange red blood cell transfusion. Nur et al[^58^](#ejh13478-bib-0058){ref-type="ref"} observed ACS in two SCD patients who presented with VOC. Subsequently, a case series by Hussain and colleagues demonstrated a milder COVID‐19 course in four SCD patients, who seemed to have benefited from early risk stratification and initiation of treatment.[^59^](#ejh13478-bib-0059){ref-type="ref"} A larger case series of 10 SCD patients described 6 confirmed cases of COVID‐19, one of which was fatal.[^23^](#ejh13478-bib-0023){ref-type="ref"} There are two independent case reports of patients with severe COVID‐19 who responded well to tocilizumab.[^21^](#ejh13478-bib-0021){ref-type="ref"}, [^22^](#ejh13478-bib-0022){ref-type="ref"} The dataset on COVID‐19 in SCD patients continues to evolve.

###### 

Summary of Published Cases of COVID‐19 in SCD

  Reference                                                                                                                 Age (years)/Gender (M/F) if Known   Complications of SCD during COVID‐19   Main treatment                                            Reported outcome
  ------------------------------------------------------------------------------------------------------------------------- ----------------------------------- -------------------------------------- --------------------------------------------------------- ------------------
  Beerkens et al[^57^](#ejh13478-bib-0057){ref-type="ref"}                                                                  21/M                                VOC, ACS                               Red blood cell (RBC) exchange transfusion                 Favorable
  Nur et al[^58^](#ejh13478-bib-0058){ref-type="ref"}                                                                       24/M                                VOC, ACS                               Oxygen and opioid therapy                                 Favorable
  Nur et al[^58^](#ejh13478-bib-0058){ref-type="ref"}                                                                       20/F                                VOC                                    Opioid therapy                                            Favorable
  De Luna et al[^21^](#ejh13478-bib-0021){ref-type="ref"}                                                                   45/M                                ACS                                    IV tocilizumab, RBC exchange transfusion                  Favorable
  Hussain et al[^59^](#ejh13478-bib-0059){ref-type="ref"}                                                                   32/M                                VOC,? ACS                              RBC exchange transfusion, intubation, ICU                 Favorable
  Hussain et al[^59^](#ejh13478-bib-0059){ref-type="ref"}                                                                   37/F                                VOC                                    IV fluids and opioid                                      Favorable
  Hussain et al[^59^](#ejh13478-bib-0059){ref-type="ref"}                                                                   22/F                                Suspected ACS                          Ceftriaxone, IV opioid                                    Favorable
  Hussain et al[^59^](#ejh13478-bib-0059){ref-type="ref"}                                                                   41/M                                VOC                                    IV fluids and opioid                                      Favorable
  Odiѐvre et al[^22^](#ejh13478-bib-0022){ref-type="ref"}                                                                   16/F                                ACS and PE                             Non‐invasive ventilation, RBC exchange transfusion, ICU   Favorable
  [^a^](#ejh13478-note-0002){ref-type="fn"}McCloskey et al[^23^](#ejh13478-bib-0023){ref-type="ref"}                        57/unknown                          Extremely Unwell                       Palliation                                                Fatal
  [^a^](#ejh13478-note-0002){ref-type="fn"}McCloskey et al (5 additional cases)[^23^](#ejh13478-bib-0023){ref-type="ref"}   Unknown range                       VOC                                    Oxygen and analgesic therapy                              Favorable

Abbreviations: ACS, Acute Chest Syndrome; F, Female; ICU, Intensive Care Unit; IV, Intravenous; M, Male; PE, Pulmonary Embolism; VOC, Vaso‐Occlusive Crisis.
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Although ACS has been reported in a few patients with sickle cell trait,[^60^](#ejh13478-bib-0060){ref-type="ref"}, [^61^](#ejh13478-bib-0061){ref-type="ref"} it appears to be exceedingly rare. An increased risk of thromboembolism in sickle cell carriers seems to be a better recognized sickling complication in heterozygotes.[^62^](#ejh13478-bib-0062){ref-type="ref"}, [^63^](#ejh13478-bib-0063){ref-type="ref"}, [^64^](#ejh13478-bib-0064){ref-type="ref"}, [^65^](#ejh13478-bib-0065){ref-type="ref"}, [^66^](#ejh13478-bib-0066){ref-type="ref"} The risk of hypercoagulability in sickle cell carriers is a subject of active investigations and discussions.[^66^](#ejh13478-bib-0066){ref-type="ref"}, [^67^](#ejh13478-bib-0067){ref-type="ref"}, [^68^](#ejh13478-bib-0068){ref-type="ref"} A prospective study of African Americans demonstrated a 2‐fold increase in the risk of pulmonary embolism in carriers of sickle cell trait.[^63^](#ejh13478-bib-0063){ref-type="ref"} A recent study demonstrated an increased risk of ischemic stroke in individuals who carry sickle cell trait and have concomitant chronic kidney disease.[^69^](#ejh13478-bib-0069){ref-type="ref"} Likewise, sickle cell trait has been associated with an increased risk of coronary artery diseases in African American men who have chronic kidney diseases.[^70^](#ejh13478-bib-0070){ref-type="ref"} The potential contributions of thrombosis related complications of sickle cell trait to the severity of COVID‐19 necessitate further studies particularly due to the higher risk of thromboembolism in COVID‐19.[^3^](#ejh13478-bib-0003){ref-type="ref"}, [^4^](#ejh13478-bib-0004){ref-type="ref"}, [^5^](#ejh13478-bib-0005){ref-type="ref"}

Although the risk of COVID‐19 induced complications in SCD is increasingly becoming topical, the potential risk in sickle cell trait warrants consideration given the greater prevalence of the heterozygous state. Healthcare providers are likely to be on the lookout for complications in SCD patients with COVID‐19 pneumonia, whereas individuals with sickle cell trait may be at an increased risk of unrecognized COVID‐19 induced sickle‐related complications. Publicizing these potential complications in carriers may help healthcare providers to include sickling complications in their differential diagnosis when assessing individuals who are from ethnicities with a high prevalence of sickle cell trait. This may facilitate prompt recognition of at‐risk individuals and the provision of individualized care for instance: anticoagulation,[^3^](#ejh13478-bib-0003){ref-type="ref"}, [^4^](#ejh13478-bib-0004){ref-type="ref"} oxygen therapy,[^59^](#ejh13478-bib-0059){ref-type="ref"} blood transfusion,[^57^](#ejh13478-bib-0057){ref-type="ref"}, [^58^](#ejh13478-bib-0058){ref-type="ref"} red blood cell exchange transfusion,[^57^](#ejh13478-bib-0057){ref-type="ref"}, [^71^](#ejh13478-bib-0071){ref-type="ref"} or extracorporeal membrane oxygenation[^72^](#ejh13478-bib-0072){ref-type="ref"}, [^73^](#ejh13478-bib-0073){ref-type="ref"}, [^74^](#ejh13478-bib-0074){ref-type="ref"} when necessary. Individuals who have sickle cell trait and are aware of their HbS genotype could be encouraged to self‐identify when presenting to healthcare providers for COVID‐19 assessment. Increasing the public awareness of sickle‐related complications may also embolden individuals who are aware of their carrier status to seek medical assessment early for COVID‐19. Recent prenatal research data suggest that many sickle cell carriers may not view SCD as a severe disorder[^75^](#ejh13478-bib-0075){ref-type="ref"}; therefore, it is possible that individuals who have sickle cell trait may benefit from an improved awareness of sickle‐related complications, particularly during the COVID‐19 pandemic.

4. CONCLUSIONS {#ejh13478-sec-0004}
==============

As highlighted by the medical literature, sickle cell trait potentially increases the risk(s) of hypercoagulability.[^30^](#ejh13478-bib-0030){ref-type="ref"}, [^63^](#ejh13478-bib-0063){ref-type="ref"}, [^64^](#ejh13478-bib-0064){ref-type="ref"}, [^65^](#ejh13478-bib-0065){ref-type="ref"}, [^66^](#ejh13478-bib-0066){ref-type="ref"} During intercurrent COVID‐19, this may lead to poor clinical outcomes. There is no reported case of COVID‐19 in sickle cell trait in the clinical scientific literature as of May 16, 2020.[^56^](#ejh13478-bib-0056){ref-type="ref"} This mini‐review is describing the putative risks to patients with COVID‐19 who may have happened to be sickle cell carriers. It is pertinent to acknowledge that there is no evidence of cause‐effect relationship(s) for the hypothesized association between sickle cell trait and COVID‐19 thus far. Although there is always the limitation of generalizability of risk, an improved awareness of the potential risk of sickle‐related complications in carriers may translate into reduced morbidity and perhaps mortality among vulnerable communities in the evolving COVID‐19 pandemic.

The high prevalence of sickle cell trait among African Americans raises fundamental clinical scientific questions on the potential roles of hemoglobin genotype in COVID‐19 severity considering the mortality trends. Genetic factors predisposing individuals to an increased risk of COVID‐19 mortality continue to be subjects of active investigations. In addition to genes and pathways that are directly targeted by COVID‐19, hemoglobin genotype may be a less evident marker of risk for COVID‐19 severity. Further molecular epidemiological analysis of COVID‐19 disease course and hemoglobin genotype in African Americans are recommended to delineate the potential risks. Given the prevalence among African Americans, strategies to improve awareness of possible risks during COVID‐19 pneumonia in sickle cell trait are suggested to individualize medical care in the burgeoning era of personalized medicine.
